3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
19
Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostate Adenocarcinoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bulbo-Spinal Atrophy, X-Linked
1
Bites and Stings
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Cytarabine
5
Whole-Body Irradiation
3
Specimen Handling
3
Injections
3
CPX-351
3
Blood Specimen Collection
3
venetoclax
2
luspatercept
2
ivosidenib
2
fludarabine phosphate
2
fludarabine
2
decitabine and cedazuridine drug combination
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Melphalan
2
Liposomes
2
Idarubicin
2
Granulocyte Colony-Stimulating Factor
2
Gemtuzumab
2
Filgrastim
2
Daunorubicin
2
Cyclosporine
2
Cyclophosphamide
2
Busulfan
2
Biopsy
2
Azacitidine
2
tocilizumab
1
selinexor
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
enzalutamide
×
30 days
×
Clear all
No trials found.